Drug Trial Radar · NCT01854918
Open-label Extension Study of Evolocumab (AMG 145) in Adults With Hyperlipidemia and Mixed Dyslipidemia
Last checked: Nov 20, 2026Latest source record: Jun 11, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
3,681
Actual
Start
Apr 23, 2013
Primary completion
May 31, 2018
Study completion May 31, 2018
Sponsor
- Lead sponsor
- AmgenAmgen (AMGN)
- Sponsor type
- Industry
- First posted
- May 16, 2013
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 85 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will contribute to the evaluation of long-term safety, tolerability and efficacy of evolocumab (AMG 145) in adults with hyperlipidemia and adults with mixed dyslipidemia.
Conditions
- Hyperlipidemia and Mixed Dyslipidemia
Interventions
EvolocumabBiological
Administered by subcutaneous injection either every 2 weeks or once a month (patient preference) using a prefilled autoinjector pen
Standard of CareDrug
Standard of care therapy as per local practices. This could include prescribed therapies and/or dietary/exercise regimes
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Adverse EventsTime frame: 48 weeks in the SOC-controlled period and up to 2 years in the All-IP period
Locations
363 sites in 25 countries. Site status is shown where the registry gives one.
Research Site
Birmingham, Alabama
Research Site
Birmingham, Alabama
Research Site
Chandler, Arizona
Research Site
Phoenix, Arizona
Research Site
Tucson, Arizona
Research Site
Little Rock, Arkansas
Research Site
Beverly Hills, California
Research Site
Carmichael, California
Research Site
Encinitas, California
Research Site
Huntington Beach, California
Research Site
Los Angeles, California
Research Site
Mission Viejo, California
Research Site
Newport Beach, California
Research Site
San Diego, California
Research Site
Santa Ana, California
Research Site
Santa Rosa, California
Research Site
Spring Valley, California
Research Site
Thousand Oaks, California
Research Site
Torrance, California
Research Site
Tustin, California
Research Site
Ventura, California
Research Site
Littleton, Colorado
Research Site
Daytona Beach, Florida
Research Site
DeLand, Florida
Research Site
Jacksonville, Florida
Research Site
Melbourne, Florida
Research Site
Miami, Florida
Research Site
Miami, Florida
Research Site
Ponte Vedra, Florida
Research Site
Port Charlotte, Florida
Research Site
Sanford, Florida
Research Site
Atlanta, Georgia
Research Site
Atlanta, Georgia
Research Site
Atlanta, Georgia
Research Site
Gainesville, Georgia
Research Site
Savannah, Georgia
Research Site
Chicago, Illinois
Research Site
Sterling, Illinois
Research Site
Indianapolis, Indiana
Research Site
Munster, Indiana
Showing 40 of 363 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.